Zochling, J and Smith, EUR, Seronegative spondyloarthritis, Best Practice & Research: Clinical Rheumatology, 24, (6) pp. 747-756. ISSN 1532-1770 (2011) [Refereed Article]
Copyright 2011 Elsevier Ltd.
Seronegative spondyloarthritis (SpA) is a group of inflammatory rheumatic diseases with common clinical and aetiological features, including axial and peripheral inflammatory arthritis, enthesitis, extra-articular manifestations and a close link to the presence of the human leucocyte antigen (HLA)-B27 epitope. Ankylosing spondylitis is the most common of the SpA diseases, with prevalence in the Caucasian population ranging between 0.15% and 1.8%, generally higher in populations with a higher background prevalence of HLA-B27 positivity. Incidence has been estimated between 0.49 (Japan) and 10 (Norway) per 100,000. The prevalence of psoriatic arthritis ranges from 0.02% to 0.2%, and the incidence in the normal population is 7.2 per 100,000 per year. In patients with existing psoriasis, the prevalence of psoriatic arthritis rises to 6-42%. The prevalence of reactive arthritis is dependent on the background incidence of gastrointestinal or genitourinary infections; incidence has been described as up to 30-40 per 100,000. SpA symptoms are present in up to 50% of patients with inflammatory bowel disease.
|Item Type:||Refereed Article|
|Keywords:||spondyloarthritis; ankylosing spondylitis; psoriatic arthritis; reactive arthritis; prevalence; epidemiology|
|Research Division:||Biomedical and Clinical Sciences|
|Research Group:||Clinical sciences|
|Research Field:||Rheumatology and arthritis|
|Objective Group:||Clinical health|
|Objective Field:||Clinical health not elsewhere classified|
|UTAS Author:||Zochling, J (Dr Jane Zochling)|
|Web of Science® Times Cited:||56|
|Deposited By:||Menzies Institute for Medical Research|
Repository Staff Only: item control page